Leptin Promotes Prostate Cancer Proliferation and Migration by Stimulating STAT3 Pathway

References

• Barry MJ, Simmons LH. Prevention of prostate cancer morbidity and mortality: primary Prevention and early detection. Med Clin North Am. 2017;101(4):787–806. doi:10.1016/j.mcna.2017.03.009
   PubMed Web of Science ®Google Scholar
• Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63(1):11–30. doi:10.3322/caac.21166
   PubMed Web of Science ®Google Scholar
• Gati A, Lajmi N, Derouiche A, Marrakchi R, Chebil M, Benammar-Elgaaied A. NY-ESO-1 expression and immunogenicity in prostate cancer patients. Tunis Med. 2011;89(10):779–83.
   PubMedGoogle Scholar
• Stangelberger A, Waldert M, Djavan B. Prostate cancer in elderly men. Rev Urol. 2008;10(2):111–9.
   PubMedGoogle Scholar
• McKay RR, Gray KP, Hayes JH, Bubley GJ, Rosenberg JE, Hussain A, Kantoff PW, Taplin M-E. Docetaxel, bevacizumab, and androgen deprivation therapy for biochemical relapse after definitive local therapy for prostate cancer. Cancer. 2015;121(15):2603–11. doi:10.1002/cncr.29398
   PubMed Web of Science ®Google Scholar
• Allott EH, Masko EM, Freedland SJ. Obesity and prostate cancer: weighing the evidence. Eur Urol. 2013;63(5):800–9. doi:10.1016/j.eururo.2012.11.013
   PubMed Web of Science ®Google Scholar
• Sierra MS, Soerjomataram I, Forman D. Etiology of prostate cancer (C61) in Central and South America. 7; 2016
   Google Scholar
• Cao H, Huang Y, Wang L, Wang H, Pang X, Li K, Dang W, Tang H, Wei L, Su M, et al. Leptin promotes migration and invasion of breast cancer cells by stimulating IL-8 production in M2 macrophages. Oncotarget. 2016;7(40):65441–53. doi:10.18632/oncotarget.11761
   PubMedGoogle Scholar
• Guh DP, Zhang W, Bansback N, Amarsi Z, Birmingham CL, Anis AH. The incidence of co-morbidities related to obesity and overweight: A systematic review and meta-analysis. BMC Public Health. 2009;9:88doi:10.1186/1471-2458-9-88
   PubMed Web of Science ®Google Scholar
• Szyszka M, Tyczewska M, Milecka P, Jopek K, Celichowski P, Malendowicz LK, Rucinski M. Effects of leptin on leptin receptor isoform expression and proliferative activity in human normal prostate and prostate cancer cell lines. Oncol Rep. 2018;39(1):182–92. doi:10.3892/or.2017.6066
   PubMed Web of Science ®Google Scholar
• Alshaker H, Sacco K, Alfraidi A, Muhammad A, Winkler M, Pchejetski D. Leptin signalling, obesity and prostate cancer: molecular and clinical perspective on the old dilemma. Oncotarget. 2015;6(34):35556–63. doi:10.18632/oncotarget.5574
   PubMedGoogle Scholar
• Andò S, Gelsomino L, Panza S, Giordano C, Bonofiglio D, Barone I, Catalano S. Obesity, leptin and breast cancer: epidemiological evidence and proposed mechanisms. Cancers. 2019;11(1):62. doi:10.3390/cancers11010062
   PubMed Web of Science ®Google Scholar
• Fruhwürth S, Vogel H, Schürmann A, et al. Novel insights into how overnutrition disrupts the hypothalamic actions of leptin. Front Endocrinol. 2018;9:89.
   PubMed Web of Science ®Google Scholar
• Myers MG, Cowley MA, Münzberg H. Mechanisms of leptin action and leptin resistance. Annu Rev Physiol. 2008;70(1):537–56. doi:10.1146/annurev.physiol.70.113006.100707
   PubMed Web of Science ®Google Scholar
• Bjørbaek C, Uotani S, da Silva B, Flier JS. Divergent signaling capacities of the long and short isoforms of the leptin receptor. J Biol Chem. 1997;272(51):32686–95. doi:10.1074/jbc.272.51.32686
   PubMed Web of Science ®Google Scholar
• Gati A, Kouidhi S, Marrakchi R, El Gaaied A, Kourda N, Derouiche A, Chebil M, Caignard A, Perier A. Obesity and renal cancer. Oncoimmunology. 2014;3(1):e27810. doi:10.4161/onci.27810
   PubMed Web of Science ®Google Scholar
• Ghasemi A, Saeidi J, Azimi-Nejad M, Hashemy SI. Leptin-induced signaling pathways in cancer cell migration and invasion. Cell Oncol Dordr. 2019;42(3):243–260. 10.1007/s13402-019-00428-0
   PubMed Web of Science ®Google Scholar
• Vidal AC, Howard LE, Moreira DM, Castro-Santamaria R, Andriole GL, Freedland SJ. Obesity increases the risk for high-grade prostate cancer: results from the REDUCE study. Cancer Epidemiol Biomark Prev Publ Am Assoc Cancer Res Cosponsored Am Soc Prev Oncol. 2014;23(12):2936–42. doi:10.1158/1055-9965.EPI-14-0795
   Google Scholar
• Møller H, Roswall N, Van Hemelrijck M, Larsen SB, Cuzick J, Holmberg L, Overvad K, Tjønneland A. Prostate cancer incidence, clinical stage and survival in relation to obesity: a prospective cohort study in Denmark. Int J Cancer. 2015;136(8):1940–7. doi:10.1002/ijc.29238
   PubMed Web of Science ®Google Scholar
• Laurent V, Guérard A, Mazerolles C, Le Gonidec S, Toulet A, Nieto L, Zaidi F, Majed B, Garandeau D, Socrier Y, et al. Periprostatic adipocytes act as a driving force for prostate cancer progression in obesity. Nat Commun. 2016;7:10230doi:10.1038/ncomms10230
   PubMed Web of Science ®Google Scholar
• Zhang Q, Sun L-j, Qi J, Yang Z-g, Huang T, Huo R-c. Periprostatic adiposity measured on magnetic resonance imaging correlates with prostate cancer aggressiveness. Urol J. 2014;11(4):1793–9.
   PubMed Web of Science ®Google Scholar
• Kim JH, Lee SY, Myung SC, Kim YS, Kim T-H, Kim MK. Clinical significance of the leptin and leptin receptor expressions in prostate tissues. Asian J Androl. 2008;10(6):923–8. doi:10.1111/j.1745-7262.2008.00438.x
   PubMed Web of Science ®Google Scholar
• Osório CF, Souza D. B d, Gallo CBM, Costa WS, Sampaio FJB. Leptin and leptin receptor expressions in prostate tumors may predict disease aggressiveness?. Acta Cir Bras. 2014;29 Suppl 3(Suppl 3):44–8. doi:10.1590/s0102-86502014001700009
   PubMed Web of Science ®Google Scholar
• Kim HS. Leptin and leptin receptor expression in breast cancer. Cancer Res Treat. 2009;41(3):155–63. doi:10.4143/crt.2009.41.3.155
   PubMed Web of Science ®Google Scholar
• Howard JM, Pidgeon GP, Reynolds JV. Leptin and gastro-intestinal malignancies. Obes Rev. 2010;11(12):863–74. doi:10.1111/j.1467-789X.2010.00718.x
   PubMed Web of Science ®Google Scholar
• Zhang Y, Liu L, Li C, Ai H. Correlation analysis between the expressions of leptin and its receptor (ObR) and clinicopathology in endometrial cancer. Cancer Biomark. 2014;14(5):353–9. doi:10.3233/CBM-140415
   PubMed Web of Science ®Google Scholar
• Uddin S, Hussain AR, Khan OS, Al-Kuraya KS. Role of dysregulated expression of leptin and leptin receptors in colorectal carcinogenesis. Tumour Biol. 2014;35(2):871–9. doi:10.1007/s13277-013-1166-4
   PubMedGoogle Scholar
• He J-Y, Wei X-H, Li S-J, Liu Y, Hu H-L, Li Z-Z, Kuang X-H, Wang L, Shi X, Yuan S-T, et al. Adipocyte-derived IL-6 and leptin promote breast Cancer metastasis via upregulation of Lysyl Hydroxylase-2 expression. Cell Commun Signal. 2018;16(1):100doi:10.1186/s12964-018-0309-z
   PubMed Web of Science ®Google Scholar
• Huang Y, Jin Q, Su M, Ji F, Wang N, Zhong C, Jiang Y, Liu Y, Zhang Z, Yang J, et al. Leptin promotes the migration and invasion of breast cancer cells by upregulating ACAT2. Cell Oncol (Dordr). 2017;40(6):537–47. doi:10.1007/s13402-017-0342-8
   PubMed Web of Science ®Google Scholar
• Li K, Wei L, Huang Y, Wu Y, Su M, Pang X, Wang N, Ji F, Zhong C, Chen T, et al. Leptin promotes breast cancer cell migration and invasion via IL-18 expression and secretion. Int J Oncol. 2016;48(6):2479–87. doi:10.3892/ijo.2016.3483
   PubMed Web of Science ®Google Scholar
• Du H, Pang M, Hou X, Yuan S, Sun L. PLOD2 in cancer research. Biomed Pharmacother. 2017;90:670–6. doi:10.1016/j.biopha.2017.04.023
   PubMed Web of Science ®Google Scholar
• Frühbeck G. Intracellular signalling pathways activated by leptin. Biochem J. 2006;393(Pt 1):7–20. doi:10.1042/BJ20051578
   PubMed Web of Science ®Google Scholar
• Sweeney G. Leptin signalling. Cell Signal. 2002;14(8):655–63. doi:10.1016/s0898-6568(02)00006-2
   PubMed Web of Science ®Google Scholar
• Johnston PA, Grandis JR. STAT3 SIGNALING: anticancer strategies and challenges. Mol Interv. 2011;11(1):18–26. doi:10.1124/mi.11.1.4
   PubMedGoogle Scholar
• Fathi N, Rashidi G, Khodadadi A, Shahi S, Sharifi S. STAT3 and apoptosis challenges in cancer. Int J Biol Macromol. 2018;117:993–1001. doi:10.1016/j.ijbiomac.2018.05.121
   PubMed Web of Science ®Google Scholar
• Xiong H, Zhang Z-G, Tian X-Q, Sun D-F, Liang Q-C, Zhang Y-J, Lu R, Chen Y-X, Fang J-Y. Inhibition of JAK1, 2/STAT3 signaling induces apoptosis, cell cycle arrest, and reduces tumor cell invasion in colorectal cancer cells. Neoplasia. 2008;10(3):287–97. doi:10.1593/neo.07971
   PubMed Web of Science ®Google Scholar
• Gao J, Tian J, Lv Y, Shi F, Kong F, Shi H, Zhao L. Leptin induces functional activation of cyclooxygenase-2 through JAK2/STAT3, MAPK/ERK, and PI3K/AKT pathways in human endometrial cancer cells. Cancer Sci. 2009;100(3):389–95. doi:10.1111/j.1349-7006.2008.01053.x
   PubMed Web of Science ®Google Scholar
• Gonzalez RR, Cherfils S, Escobar M, Yoo JH, Carino C, Styer AK, Sullivan BT, Sakamoto H, Olawaiye A, Serikawa T, et al. Leptin signaling promotes the growth of mammary tumors and increases the expression of vascular endothelial growth factor (VEGF) and its receptor type two (VEGF-R2). J Biol Chem. 2006;281(36):26320–8. doi:10.1074/jbc.M601991200
   PubMed Web of Science ®Google Scholar
• Jiang H, Yu J, Guo H, Song H, Chen S. Upregulation of survivin by leptin/STAT3 signaling in MCF-7 cells. Biochem Biophys Res Commun. 2008;368(1):1–5. doi:10.1016/j.bbrc.2007.04.004
   PubMed Web of Science ®Google Scholar
• Ahn J-H, Choi YS, Choi J-H. Leptin promotes human endometriotic cell migration and invasion by up-regulating MMP-2 through the JAK2/STAT3 signaling pathway. Mol Hum Reprod. 2015;21(10):792–802. doi:10.1093/molehr/gav039
   PubMed Web of Science ®Google Scholar
• Fan Y, Gan Y, Shen Y, Cai X, Song Y, Zhao F, Yao M, Gu J, Tu H. Leptin signaling enhances cell invasion and promotes the metastasis of human pancreatic cancer via increasing MMP-13 production. Oncotarget. 2015;6(18):16120–34. doi:10.18632/oncotarget.3878
   PubMedGoogle Scholar
• Ding Y, Cao Y, Wang B, Wang L, Zhang Y, Zhang D, Chen X, Li M, Wang C. APPL1-mediating leptin signaling contributes to proliferation and migration of cancer cells. PloS One. 2016;11(11):e0166172doi:10.1371/journal.pone.0166172
   PubMed Web of Science ®Google Scholar
• Thiery JP, Acloque H, Huang RYJ, Nieto MA. Epithelial-mesenchymal transitions in development and disease. Cell. 2009;139(5):871–90. doi:10.1016/j.cell.2009.11.007
   PubMed Web of Science ®Google Scholar
• Li S, Qin X, Chai S, Qu C, Wang X, Zhang H. Modulation of E-cadherin expression promotes migration ability of esophageal cancer cells. Sci Rep. 2016;6:21713doi:10.1038/srep21713
   PubMed Web of Science ®Google Scholar
• Chang C-C, Wu M-J, Yang J-Y, Camarillo IG, Chang C-J. Leptin-STAT3-G9a Signaling Promotes Obesity-Mediated Breast Cancer Progression. Cancer Res. 2015;75(11):2375–86. doi:10.1158/0008-5472.CAN-14-3076
   PubMed Web of Science ®Google Scholar
• Park JW, Zhao L, Willingham MC, Cheng S-Y. Inhibition of STAT3 signaling blocks obesity-induced mammary hyperplasia in a mouse model. Am J Cancer Res. 2017;7:727–39.
   PubMed Web of Science ®Google Scholar
• Park JW, Han CR, Zhao L, Willingham MC, Cheng S-y. Inhibition of STAT3 activity delays obesity-induced thyroid carcinogenesis in a mouse model. Endocr Relat Cancer. 2016;23(1):53–63. doi:10.1530/ERC-15-0417
   PubMed Web of Science ®Google Scholar